2023
DOI: 10.1016/s1470-2045(23)00334-0
|View full text |Cite
|
Sign up to set email alerts
|

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Reinhard Dummer,
Paola Queirolo,
Pauline Gerard Duhard
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(9 citation statements)
references
References 26 publications
0
9
0
Order By: Relevance
“…This was a phase II multicenter trial, which studied the efficacy of the combination of atezolizumab, cobimetinib, and vemurafenib in patients with BRAF-mutated metastatic melanoma with brain metastasis. 33 This study allowed for the enrollment of patients with symptomatic brain metastasis and those receiving corticosteroids or anticonvulsants. A total of 80 patients were enrolled and divided in 2 cohorts.…”
Section: Triplet Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…This was a phase II multicenter trial, which studied the efficacy of the combination of atezolizumab, cobimetinib, and vemurafenib in patients with BRAF-mutated metastatic melanoma with brain metastasis. 33 This study allowed for the enrollment of patients with symptomatic brain metastasis and those receiving corticosteroids or anticonvulsants. A total of 80 patients were enrolled and divided in 2 cohorts.…”
Section: Triplet Therapymentioning
confidence: 99%
“…The first clinical trial to report the intracranial efficacy of the combination of targeted therapy and immunotherapy in MBMs was the TRICOTEL study. This was a phase II multicenter trial, which studied the efficacy of the combination of atezolizumab, cobimetinib, and vemurafenib in patients with BRAF-mutated metastatic melanoma with brain metastasis 33 . This study allowed for the enrollment of patients with symptomatic brain metastasis and those receiving corticosteroids or anticonvulsants.…”
Section: Systemic Therapies In Melanoma Brain Metastasesmentioning
confidence: 99%
“…Of 11 patients with BRAF mutations on more than 2 mg of dexamethasone per day, four were able to rapidly taper their corticosteroid to zero over 28 days (prior to ICI initiation), five continued on greater than 2 mg per day during ICI initiation, and two discontinued treatment early. 77 Combining BRAF-MEK inhibitors with PD-1/PD-L1 inhibitors has been trialled and considered as a bridging option in symptomatic MBM, but has limited data to support it as routine practice. A case series of five patients, all with symptomatic brain metastases, demonstrated that the combination of BRAF-MEK inhibitors and PD-1 inhibitor (and radiation) could produce durable responses, with two patients experiencing a complete response, and more than 3 years without progression.…”
Section: Interventionmentioning
confidence: 99%
“…In the BRAF mutation cohort, the response rate was 42%, versus 27% in the BRAF wild‐type cohort. Of 11 patients with BRAF mutations on more than 2 mg of dexamethasone per day, four were able to rapidly taper their corticosteroid to zero over 28 days (prior to ICI initiation), five continued on greater than 2 mg per day during ICI initiation, and two discontinued treatment early 77 …”
Section: Systemic Therapymentioning
confidence: 99%
“…In the last few years, the need to detect the right drug, with the right dosage at the right time to the right patient has increased the interest of pharmaceutical companies and researchers ( 80 ). This “revolution” has been spreading in health care, particularly in oncology, providing effective tailored therapeutic strategies based on epigenomic, proteomic, and genomic profiles of each patient ( 81 85 ). Simultaneously, the growing development of medical engineering and miniaturizing devices, increased patients’ compliance and quality of life.…”
Section: Future Directionmentioning
confidence: 99%